These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1068 related items for PubMed ID: 25818596

  • 1. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J, Fitzpatrick JM.
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [Abstract] [Full Text] [Related]

  • 2. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H, Saito A.
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [Abstract] [Full Text] [Related]

  • 3. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
    Graham L, Schweizer MT.
    Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
    [Abstract] [Full Text] [Related]

  • 4. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
    Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.
    Clin Cancer Res; 2014 Jun 15; 20(12):3198-3210. PubMed ID: 24740322
    [Abstract] [Full Text] [Related]

  • 5. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.
    Eur Urol; 2015 Mar 15; 67(3):470-9. PubMed ID: 25306226
    [Abstract] [Full Text] [Related]

  • 6. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
    Sternberg CN.
    Future Oncol; 2019 May 15; 15(13):1437-1457. PubMed ID: 30848157
    [Abstract] [Full Text] [Related]

  • 7. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME.
    Eur Urol; 2018 Jan 15; 73(1):4-8. PubMed ID: 28851578
    [Abstract] [Full Text] [Related]

  • 8. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.
    Eur Urol; 2015 Jun 15; 67(6):981-985. PubMed ID: 25484141
    [Abstract] [Full Text] [Related]

  • 9. Drug Resistance of Enzalutamide in CRPC.
    Chen X, Lu J, Xia L, Li G.
    Curr Drug Targets; 2018 Jun 15; 19(6):613-620. PubMed ID: 28413979
    [Abstract] [Full Text] [Related]

  • 10. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.
    Eur Urol; 2016 Oct 15; 70(4):599-608. PubMed ID: 27117751
    [Abstract] [Full Text] [Related]

  • 11. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.
    Cancer; 2018 Mar 15; 124(6):1216-1224. PubMed ID: 29266182
    [Abstract] [Full Text] [Related]

  • 12. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ.
    Eur Urol; 2015 Jan 15; 67(1):53-60. PubMed ID: 24882673
    [Abstract] [Full Text] [Related]

  • 13. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P, Rivera A, Muthima K, Olveda N, Muchalski H, Chen QH.
    Molecules; 2020 May 24; 25(10):. PubMed ID: 32456317
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z, Cheng L, Li J, Farah E, Atallah NM, Pascuzzi PE, Gupta S, Liu X.
    Cancer Res; 2018 Jun 15; 78(12):3147-3162. PubMed ID: 29700003
    [Abstract] [Full Text] [Related]

  • 15. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
    Baciarello G, Sternberg CN.
    Crit Rev Oncol Hematol; 2016 Oct 15; 106():14-24. PubMed ID: 27637350
    [Abstract] [Full Text] [Related]

  • 16. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
    Loriot Y, Eymard JC, Patrikidou A, Ileana E, Massard C, Albiges L, Di Palma M, Escudier B, Fizazi K.
    Eur J Cancer; 2015 Sep 15; 51(14):1946-52. PubMed ID: 26208462
    [Abstract] [Full Text] [Related]

  • 17. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
    Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, Wang G, Huang H.
    Oncotarget; 2016 Jun 21; 7(25):38551-38565. PubMed ID: 27221037
    [Abstract] [Full Text] [Related]

  • 18. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L, Tien JC, Vo J, Tan M, Parolia A, Zhang Y, Wang L, Qiao Y, Shukla S, Wang X, Zheng H, Su F, Jing X, Luo E, Delekta A, Juckette KM, Xu A, Cao X, Alva AS, Kim Y, MacLeod AR, Chinnaiyan AM.
    Cancer Res; 2018 Oct 15; 78(20):5731-5740. PubMed ID: 30135193
    [Abstract] [Full Text] [Related]

  • 19. Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.
    Keating GM.
    Drugs Aging; 2015 Mar 15; 32(3):243-9. PubMed ID: 25711765
    [Abstract] [Full Text] [Related]

  • 20. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ, Milowsky MI, Whang YE.
    Clin Pharmacol Ther; 2015 Dec 15; 98(6):582-9. PubMed ID: 26331358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.